Cargando…

Development and validation of COEWS (COVID-19 Early Warning Score) for hospitalized COVID-19 with laboratory features: A multicontinental retrospective study

BACKGROUND: The emergence of new SARS-CoV-2 variants with significant immune-evasiveness, the relaxation of measures for reducing the number of infections, the waning of immune protection (particularly in high-risk population groups), and the low uptake of new vaccine boosters, forecast new waves of...

Descripción completa

Detalles Bibliográficos
Autores principales: Klén, Riku, Huespe, Ivan A, Gregalio, Felipe Aníbal, Lalueza Blanco, Antonio Lalueza, Pedrera Jimenez, Miguel, Garcia Barrio, Noelia, Valdez, Pascual Ruben, Mirofsky, Matias A, Boietti, Bruno, Gómez-Huelgas, Ricardo, Casas-Rojo, José Manuel, Antón-Santos, Juan Miguel, Pollan, Javier Alberto, Gómez-Varela, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10479961/
https://www.ncbi.nlm.nih.gov/pubmed/37615346
http://dx.doi.org/10.7554/eLife.85618
_version_ 1785101703265124352
author Klén, Riku
Huespe, Ivan A
Gregalio, Felipe Aníbal
Lalueza Blanco, Antonio Lalueza
Pedrera Jimenez, Miguel
Garcia Barrio, Noelia
Valdez, Pascual Ruben
Mirofsky, Matias A
Boietti, Bruno
Gómez-Huelgas, Ricardo
Casas-Rojo, José Manuel
Antón-Santos, Juan Miguel
Pollan, Javier Alberto
Gómez-Varela, David
author_facet Klén, Riku
Huespe, Ivan A
Gregalio, Felipe Aníbal
Lalueza Blanco, Antonio Lalueza
Pedrera Jimenez, Miguel
Garcia Barrio, Noelia
Valdez, Pascual Ruben
Mirofsky, Matias A
Boietti, Bruno
Gómez-Huelgas, Ricardo
Casas-Rojo, José Manuel
Antón-Santos, Juan Miguel
Pollan, Javier Alberto
Gómez-Varela, David
author_sort Klén, Riku
collection PubMed
description BACKGROUND: The emergence of new SARS-CoV-2 variants with significant immune-evasiveness, the relaxation of measures for reducing the number of infections, the waning of immune protection (particularly in high-risk population groups), and the low uptake of new vaccine boosters, forecast new waves of hospitalizations and admission to intensive care units. There is an urgent need for easily implementable and clinically effective Early Warning Scores (EWSs) that can predict the risk of complications within the next 24–48 hr. Although EWSs have been used in the evaluation of COVID-19 patients, there are several clinical limitations to their use. Moreover, no models have been tested on geographically distinct populations or population groups with varying levels of immune protection. METHODS: We developed and validated COVID-19 Early Warning Score (COEWS), an EWS that is automatically calculated solely from laboratory parameters that are widely available and affordable. We benchmarked COEWS against the widely used NEWS2. We also evaluated the predictive performance of vaccinated and unvaccinated patients. RESULTS: The variables of the COEWS predictive model were selected based on their predictive coefficients and on the wide availability of these laboratory variables. The final model included complete blood count, blood glucose, and oxygen saturation features. To make COEWS more actionable in real clinical situations, we transformed the predictive coefficients of the COEWS model into individual scores for each selected feature. The global score serves as an easy-to-calculate measure indicating the risk of a patient developing the combined outcome of mechanical ventilation or death within the next 48 hr. The discrimination in the external validation cohort was 0.743 (95% confidence interval [CI]: 0.703–0.784) for the COEWS score performed with coefficients and 0.700 (95% CI: 0.654–0.745) for the COEWS performed with scores. The area under the receiver operating characteristic curve (AUROC) was similar in vaccinated and unvaccinated patients. Additionally, we observed that the AUROC of the NEWS2 was 0.677 (95% CI: 0.601–0.752) in vaccinated patients and 0.648 (95% CI: 0.608–0.689) in unvaccinated patients. CONCLUSIONS: The COEWS score predicts death or MV within the next 48 hr based on routine and widely available laboratory measurements. The extensive external validation, its high performance, its ease of use, and its positive benchmark in comparison with the widely used NEWS2 position COEWS as a new reference tool for assisting clinical decisions and improving patient care in the upcoming pandemic waves. FUNDING: University of Vienna.
format Online
Article
Text
id pubmed-10479961
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher eLife Sciences Publications, Ltd
record_format MEDLINE/PubMed
spelling pubmed-104799612023-09-06 Development and validation of COEWS (COVID-19 Early Warning Score) for hospitalized COVID-19 with laboratory features: A multicontinental retrospective study Klén, Riku Huespe, Ivan A Gregalio, Felipe Aníbal Lalueza Blanco, Antonio Lalueza Pedrera Jimenez, Miguel Garcia Barrio, Noelia Valdez, Pascual Ruben Mirofsky, Matias A Boietti, Bruno Gómez-Huelgas, Ricardo Casas-Rojo, José Manuel Antón-Santos, Juan Miguel Pollan, Javier Alberto Gómez-Varela, David eLife Epidemiology and Global Health BACKGROUND: The emergence of new SARS-CoV-2 variants with significant immune-evasiveness, the relaxation of measures for reducing the number of infections, the waning of immune protection (particularly in high-risk population groups), and the low uptake of new vaccine boosters, forecast new waves of hospitalizations and admission to intensive care units. There is an urgent need for easily implementable and clinically effective Early Warning Scores (EWSs) that can predict the risk of complications within the next 24–48 hr. Although EWSs have been used in the evaluation of COVID-19 patients, there are several clinical limitations to their use. Moreover, no models have been tested on geographically distinct populations or population groups with varying levels of immune protection. METHODS: We developed and validated COVID-19 Early Warning Score (COEWS), an EWS that is automatically calculated solely from laboratory parameters that are widely available and affordable. We benchmarked COEWS against the widely used NEWS2. We also evaluated the predictive performance of vaccinated and unvaccinated patients. RESULTS: The variables of the COEWS predictive model were selected based on their predictive coefficients and on the wide availability of these laboratory variables. The final model included complete blood count, blood glucose, and oxygen saturation features. To make COEWS more actionable in real clinical situations, we transformed the predictive coefficients of the COEWS model into individual scores for each selected feature. The global score serves as an easy-to-calculate measure indicating the risk of a patient developing the combined outcome of mechanical ventilation or death within the next 48 hr. The discrimination in the external validation cohort was 0.743 (95% confidence interval [CI]: 0.703–0.784) for the COEWS score performed with coefficients and 0.700 (95% CI: 0.654–0.745) for the COEWS performed with scores. The area under the receiver operating characteristic curve (AUROC) was similar in vaccinated and unvaccinated patients. Additionally, we observed that the AUROC of the NEWS2 was 0.677 (95% CI: 0.601–0.752) in vaccinated patients and 0.648 (95% CI: 0.608–0.689) in unvaccinated patients. CONCLUSIONS: The COEWS score predicts death or MV within the next 48 hr based on routine and widely available laboratory measurements. The extensive external validation, its high performance, its ease of use, and its positive benchmark in comparison with the widely used NEWS2 position COEWS as a new reference tool for assisting clinical decisions and improving patient care in the upcoming pandemic waves. FUNDING: University of Vienna. eLife Sciences Publications, Ltd 2023-08-24 /pmc/articles/PMC10479961/ /pubmed/37615346 http://dx.doi.org/10.7554/eLife.85618 Text en © 2023, Klén, Huespe et al https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Epidemiology and Global Health
Klén, Riku
Huespe, Ivan A
Gregalio, Felipe Aníbal
Lalueza Blanco, Antonio Lalueza
Pedrera Jimenez, Miguel
Garcia Barrio, Noelia
Valdez, Pascual Ruben
Mirofsky, Matias A
Boietti, Bruno
Gómez-Huelgas, Ricardo
Casas-Rojo, José Manuel
Antón-Santos, Juan Miguel
Pollan, Javier Alberto
Gómez-Varela, David
Development and validation of COEWS (COVID-19 Early Warning Score) for hospitalized COVID-19 with laboratory features: A multicontinental retrospective study
title Development and validation of COEWS (COVID-19 Early Warning Score) for hospitalized COVID-19 with laboratory features: A multicontinental retrospective study
title_full Development and validation of COEWS (COVID-19 Early Warning Score) for hospitalized COVID-19 with laboratory features: A multicontinental retrospective study
title_fullStr Development and validation of COEWS (COVID-19 Early Warning Score) for hospitalized COVID-19 with laboratory features: A multicontinental retrospective study
title_full_unstemmed Development and validation of COEWS (COVID-19 Early Warning Score) for hospitalized COVID-19 with laboratory features: A multicontinental retrospective study
title_short Development and validation of COEWS (COVID-19 Early Warning Score) for hospitalized COVID-19 with laboratory features: A multicontinental retrospective study
title_sort development and validation of coews (covid-19 early warning score) for hospitalized covid-19 with laboratory features: a multicontinental retrospective study
topic Epidemiology and Global Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10479961/
https://www.ncbi.nlm.nih.gov/pubmed/37615346
http://dx.doi.org/10.7554/eLife.85618
work_keys_str_mv AT klenriku developmentandvalidationofcoewscovid19earlywarningscoreforhospitalizedcovid19withlaboratoryfeaturesamulticontinentalretrospectivestudy
AT huespeivana developmentandvalidationofcoewscovid19earlywarningscoreforhospitalizedcovid19withlaboratoryfeaturesamulticontinentalretrospectivestudy
AT gregaliofelipeanibal developmentandvalidationofcoewscovid19earlywarningscoreforhospitalizedcovid19withlaboratoryfeaturesamulticontinentalretrospectivestudy
AT laluezablancoantoniolalueza developmentandvalidationofcoewscovid19earlywarningscoreforhospitalizedcovid19withlaboratoryfeaturesamulticontinentalretrospectivestudy
AT pedrerajimenezmiguel developmentandvalidationofcoewscovid19earlywarningscoreforhospitalizedcovid19withlaboratoryfeaturesamulticontinentalretrospectivestudy
AT garciabarrionoelia developmentandvalidationofcoewscovid19earlywarningscoreforhospitalizedcovid19withlaboratoryfeaturesamulticontinentalretrospectivestudy
AT valdezpascualruben developmentandvalidationofcoewscovid19earlywarningscoreforhospitalizedcovid19withlaboratoryfeaturesamulticontinentalretrospectivestudy
AT mirofskymatiasa developmentandvalidationofcoewscovid19earlywarningscoreforhospitalizedcovid19withlaboratoryfeaturesamulticontinentalretrospectivestudy
AT boiettibruno developmentandvalidationofcoewscovid19earlywarningscoreforhospitalizedcovid19withlaboratoryfeaturesamulticontinentalretrospectivestudy
AT gomezhuelgasricardo developmentandvalidationofcoewscovid19earlywarningscoreforhospitalizedcovid19withlaboratoryfeaturesamulticontinentalretrospectivestudy
AT casasrojojosemanuel developmentandvalidationofcoewscovid19earlywarningscoreforhospitalizedcovid19withlaboratoryfeaturesamulticontinentalretrospectivestudy
AT antonsantosjuanmiguel developmentandvalidationofcoewscovid19earlywarningscoreforhospitalizedcovid19withlaboratoryfeaturesamulticontinentalretrospectivestudy
AT pollanjavieralberto developmentandvalidationofcoewscovid19earlywarningscoreforhospitalizedcovid19withlaboratoryfeaturesamulticontinentalretrospectivestudy
AT gomezvareladavid developmentandvalidationofcoewscovid19earlywarningscoreforhospitalizedcovid19withlaboratoryfeaturesamulticontinentalretrospectivestudy